Precision BioSciences Inc. (NASDAQ:DTIL) shares traded 9.23% higher at $0.64 on Wall Street last session.
In accordance with the data, 6 analysts cover Precision BioSciences Inc. (NASDAQ:DTIL). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $17.00 and a low of $1.00, we find $5.00. Given the previous closing price of $0.59, this indicates a potential upside of 747.46 percent. DTIL stock price is now -11.26% away from the 50-day moving average and -39.69% away from the 200-day moving average. The market capitalization of the company currently stands at $66.84M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
It has been rated a hold by 2 analysts and a buy by 4. Brokers who have rated the stock have averaged $6.50 as their price target over the next twelve months.
With the price target of $7, BMO Capital Markets recently initiated with Outperform rating for Precision BioSciences Inc. (NASDAQ: DTIL).
In other news, Scimeca Dario, General Counsel and Secretary sold 13,361 shares of the company’s stock on Jun 08. The stock was sold for $10,021 at an average price of $0.75. Upon completion of the transaction, the General Counsel and Secretary now directly owns 68,473 shares in the company, valued at $43822.72. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 27, Chief Medical Officer List Alan sold 7,771 shares of the business’s stock. A total of $6,139 was realized by selling the stock at an average price of $0.79. This leaves the insider owning 56,496 shares of the company worth $36157.44. Insiders disposed of 87,421 shares of company stock worth roughly $55949.44 over the past 1 year. A total of 1.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DTIL stock. A new stake in Precision BioSciences Inc. shares was purchased by JACOBS LEVY EQUITY MANAGEMENT, INC during the first quarter worth $504,000. BANK OF MONTREAL /CAN/ invested $191,000 in shares of DTIL during the first quarter. In the first quarter, LANDSCAPE CAPITAL MANAGEMENT, L.L.C. acquired a new stake in Precision BioSciences Inc. valued at approximately $65,000. CITIGROUP INC acquired a new stake in DTIL for approximately $30,000. DARK FOREST CAPITAL MANAGEMENT LP purchased a new stake in DTIL valued at around $12,000 in the second quarter. In total, there are 134 active investors with 47.40% ownership of the company’s stock.
Precision BioSciences Inc. (NASDAQ: DTIL) opened at $0.5880 on Monday. During the past 12 months, Precision BioSciences Inc. has had a low of $0.51 and a high of $2.12. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.60, and a quick ratio of 3.60. The fifty day moving average price for DTIL is $0.7178 and a two-hundred day moving average price translates $1.0573 for the stock.
The latest earnings results from Precision BioSciences Inc. (NASDAQ: DTIL) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.23, inline with analysts’ expectations of -$0.23. This compares to -$0.46 EPS in the same period last year. The company reported revenue of $8.78 million for the quarter, compared to $3.32 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 164.7 percent. For the current quarter, analysts expect DTIL to generate $6.38M in revenue.
Precision BioSciences Inc.(DTIL) Company Profile
Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
